Chapple Christopher, Khullar Vik, Gabriel Zahava, Dooley Julie Ann
Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Urology Research, J Floor Office, Glossop Road, Sheffield, S102JF, UK.
Eur Urol. 2005 Jul;48(1):5-26. doi: 10.1016/j.eururo.2005.02.024. Epub 2005 Mar 22.
To evaluate the tolerability, safety and efficacy of antimuscarinic drugs used to treat overactive bladder and to identify any differences between individual antimuscarinics.
Medline, Embase, CCTR and Cinahl databases were searched for published RCTs including an antimuscarinic agent from 1966 to August 2004. Data from included trials were extracted and meta-analysed where possible.
Fifty-six trials were included. The antimuscarinics were found to be safe and efficacious. All antimuscarinics apart from oxybutynin IR were found to be well tolerated. Dry mouth was the most commonly reported adverse event and no drug was associated with an increase in any serious adverse event. There were significant differences between the antimuscarinics in rates of withdrawal and rates and range of adverse events and efficacy outcomes.
The antimuscarinics have different tolerability and safety profiles, which are clinically significant.
评估用于治疗膀胱过度活动症的抗毒蕈碱药物的耐受性、安全性和疗效，并确定各抗毒蕈碱药物之间的差异。
检索Medline、Embase、CCTR和Cinahl数据库，查找1966年至2004年8月期间发表的包含抗毒蕈碱药物的随机对照试验。提取纳入试验的数据，并尽可能进行荟萃分析。
纳入56项试验。发现抗毒蕈碱药物安全有效。除速释奥昔布宁外，所有抗毒蕈碱药物耐受性良好。口干是最常报告的不良事件，没有药物与任何严重不良事件增加相关。抗毒蕈碱药物在撤药率、不良事件发生率及范围和疗效结果方面存在显著差异。
抗毒蕈碱药物具有不同的耐受性和安全性特征，具有临床意义。
